← All articles

Total current articles · 5,230

COVID-19 Vaccination in Israel

Published

01In brief

COVID-19 Vaccination in Israel was a nationwide public-health campaign launched in December 2020, initially using the Pfizer-BioNTech vaccine and prioritizing older people, health-care workers, and others at elevated risk. Israel’s rapid rollout made it one of the earliest countries to reach high vaccination coverage, while its health-care networks and digital records supported delivery and the assessment of vaccine performance. The campaign later expanded to younger age groups, introduced booster doses in 2021, and included fourth doses for some older adults. It was marked by uneven uptake and disputes over vaccine access and responsibilities toward Palestinians. Data-sharing and procurement decisions drew scrutiny, and an audit identified major deficiencies in the recording and analysis of reported adverse events.

02Background and Preparations

Israel’s vaccination program followed agreements to procure vaccines from several manufacturers. A contemporary account reported that Israel reached an agreement with Moderna in June 2020, announced agreements with Pfizer and AstraZeneca in November, and received its first Pfizer shipment on December 9. The Pfizer-BioNTech vaccine was authorized for emergency use in Israel on December 6, before the Health Ministry launched the nationwide campaign later that month.[1][2]

The Health Ministry’s December 10 priority plan placed about 250,000 health-system workers first, followed by approximately 350,000 residents of institutions for older people and their carers. Subsequent priorities included older people according to age and vaccine availability; people with underlying conditions, particularly obesity, diabetes, and organ transplants; residents of mental-health institutions; teachers, estimated at about 200,000; and IDF soldiers. Health funds could vaccinate people outside the priority groups from the campaign’s beginning when their capacity allowed.[9]

Initial eligibility reflected the evidence and policy assumptions at the time. The ministry said children under 16 had not been included in vaccine trials and would not initially be vaccinated. Its guidance also said vaccination had not been studied in pregnant women and that the ministry would wait, while noting there was no information indicating a risk during pregnancy. People with severe allergic reactions and those who had recovered from COVID-19 were also excluded under the initial guidance.[9]

Sources describe the opening of the campaign somewhat differently. A Ministry of Health-hosted study dates the nationwide launch to December 20 and says the first priority age group was people aged 65 and older, alongside health-care workers and long-term-care residents. The State Comptroller describes the campaign as beginning at the end of December and gives an initial age threshold of 60, while also listing medically at-risk people under 60, medical staff, and some economically essential workers. These descriptions may refer to different stages or definitions of the early rollout.[2][10]

The rollout depended on advance logistics for a vaccine requiring ultra-cold storage and distribution in quantities smaller than the large shipment units. Teva Pharmaceutical Industries’ logistics unit SLE handled doses in an underground facility near Israel’s main airport. Thirty freezers set to minus 70°C could hold five million doses; staff divided shipments into bundles as small as 100 doses for delivery to roughly 400 vaccination centres. Israeli teams also repacked large frozen pallets into insulated boxes for remote locations, allowing clinics and larger centres to operate in parallel.[1]

03Launch and Rapid Expansion

Israel’s Ministry of Health launched the nationwide vaccination campaign on December 20, 2020. The first phase sought to administer two doses to roughly 6.5 million people aged 16 and older, and vaccinations were initially delivered at about 400 sites. Records were entered into patients’ electronic health records and sent to a national database, creating a system for monitoring the campaign and evaluating outcomes.[2]

Universal health-care coverage and computerized health networks helped identify people in priority groups and contact them. The logistics system was designed to limit waste as well as to distribute doses across large and small sites. At one point in the early campaign, Israel was administering about 150,000 shots per day; Haifa had a drive-through vaccination site. A contemporary report said the country had reached nearly 15% of its population of 9.3 million within about two weeks of the campaign’s start.[1]

By late January, the initial age restrictions had loosened quickly. In an interview recorded on January 28, Jerusalem Post correspondent Lahav Harkov said eligibility had expanded from people aged 60 and older to people aged 35 and older, as well as 16- to 18-year-olds. She said the younger teenagers were being vaccinated so they could take exams and finish high school. Harkov estimated that more than 20% of the population had been vaccinated by then, while emphasizing that she did not have the exact figure for that particular day.[11]

Contemporaneous measures used different dates and definitions. A reference page reports that more than a quarter of Israel’s population had received at least one dose by the end of January.[12] On February 2, a report put the number with at least one dose at about 3.2 million—34% of the population—and the number with a second Pfizer dose at 1.8 million.[13] By March 25, 5,203,644 people had received at least one dose and 4,655,955 had received two; more than half the total population was described as fully vaccinated.[14]

The numbers are not directly interchangeable because reports count different dates, age groups, and dose thresholds. The State Comptroller found that more than half of Israel’s population aged 16 and older had received two doses by March 31, 2021. Its comparison of total-population coverage put two-dose uptake at 50.9% in Israel at the end of March, against 5.1% in the European Union and a global average of 1.8%; Israel ranked second after Gibraltar in that comparison.[8]

04Vaccination Access and Eligibility

As supplies and eligibility expanded, Israel used health funds, clinics, dedicated centres, and mobile outreach to reach different communities. A reference account describes more than 80 vaccination stations and more than 28 mobile stations serving Arab communities. Authorities also added centres in Arab towns amid concerns about lower uptake among Israeli Arabs, and the government stepped up public messaging against false claims about side effects.[12][1]

East Jerusalem presented particular access and communication challenges. In a February 2021 discussion, a speaker estimated coverage at about 20% shortly before the event, but noted that the location of some vaccinated residents could not be identified in the available figures. The reported rate reached 44% by February 26. Health maintenance organizations operated centres responsible for most vaccinations, while the municipality and partners also brought vaccination points into neighbourhoods.[15]

An example of that approach was a school-based operation in Abu Tor on February 15, 2021, which drew 600 people. The account describes coordination among school principals, community administrations, the Home Front Command, health organizations, and other institutions. Outreach included Arabic-language communication and efforts to address misinformation and concerns about safety and effectiveness; the discussion also noted remaining access and engagement challenges in some neighbourhoods.[15]

The State Comptroller’s age-group chronology records that eligibility expanded to people aged 16 and older in January 2021, ages 12–15 in June, and ages 5–11 in November. Israel also established emergency, compassionate vaccination for some high-risk adolescents aged 12–15 before U.S. Food and Drug Administration approval in May. From February 12, eligible adolescents with conditions associated with severe COVID-19 or MIS-C, or with severely immunosuppressed household members, could be referred to the Health Ministry through the four health maintenance organizations.[10][16]

By March 15, the compassionate-use report said 607 adolescents had been approved, 333 had received one dose, and 92 had received two. It recorded one positive COVID-19 test four days after vaccination and no adverse effects in the group. From July 27, 2021, the same process was applied to children aged 5–11.[16]

05Vaccination Coverage and Unequal Uptake

Coverage rose rapidly in the first months, especially among older adults, but uptake varied across population groups and later doses. As of April 3, 2021, 4,714,932 people aged 16 and older—72.1% of that age group—were fully vaccinated with two doses. Among those aged 65 and older, the two-dose figure was 90.0%. More than 10 million doses had been administered to over 5.2 million people, and Pfizer-BioNTech was then the only COVID-19 vaccine available in Israel.[2]

The same April snapshot showed marked differences by population sector: two-dose coverage among people aged 16 and older was 79.9% in the general Jewish population, 54.6% in the Arab population, and 42.8% in the ultra-Orthodox population. A separate March estimate for residents aged 50 and older put receipt of at least one dose at 89% among other Israelis, compared with 68% among Israeli Arabs and about 72% among Haredi Orthodox Jews. These statistics refer to different dates and age and dose measures and should not be read as a single directly comparable series.[2][17]

A retrospective study using Ministry of Health data covering 98.8% of the population traced cases, hospitalizations, mortality, and vaccination across four pandemic waves between March 11, 2020, and December 1, 2021. It found that by December 2021 double-dose uptake was 71% and 74% in the two highest socioeconomic clusters, compared with 43% and 27% in the two lowest. Third-dose uptake was 57%–60% in the highest clusters and 25%–31% in the lowest. Socioeconomic differences were larger among younger people, widened from first to third doses, and occurred despite greater COVID-19 burden in disadvantaged groups.[5]

Later-dose gaps were also apparent among older adults in the Arab and ultra-Orthodox localities examined by the State Comptroller. First-dose coverage among people aged 60 and older was 97% overall, against 88% in the Arab localities and 84% in the ultra-Orthodox localities. From the first to the third dose, coverage fell by eight percentage points overall, 22 points in Arab localities, and 14 points in ultra-Orthodox localities. By the fourth dose, the gap relative to the general population reached 34 and 26 percentage points, respectively; third-dose coverage among older adults in the examined localities was 60%–62%, compared with 86% overall.[8]

A review of Israel’s pandemic response identified cross-sector cooperation among the Ministry of Health, health-care providers, academia, and the military, as well as prioritization and computerized databases, as strengths supporting uptake and impact assessment. It also identified staffing shortages, difficulty maintaining quarantine in underprivileged communities, and challenges of trust and cooperation—especially among ethnic and religious minorities—as issues requiring attention.[18]

06Effectiveness and Health Outcomes

Israeli studies provided early evidence on the Pfizer-BioNTech vaccine’s performance in real-world use. A nationwide observational study matched 596,618 newly vaccinated people with an equal number of unvaccinated controls. Participants in the vaccinated group received their first dose between December 20, 2020, and February 1, 2021. At least seven days after the second dose, estimated effectiveness was 92% against documented infection, 94% against symptomatic COVID-19, 87% against hospitalization, and 92% against severe disease. The study described its results as consistent with the randomized trial.[19]

A separate nationwide analysis used Israeli surveillance data for residents aged 16 and older from January 24 to April 3, 2021. At least seven days after the second dose, it estimated two-dose effectiveness at 95.3% against infection, 97.0% against symptomatic disease, 97.2% against COVID-19 hospitalization, 97.5% against severe or critical hospitalization, and 96.7% against death. The authors cautioned that the study was observational rather than randomized: unmeasured differences between vaccinated and unvaccinated people, different testing policies, and differences in behaviour could affect estimates. They also noted the short follow-up and advised caution in applying the findings to other settings.[2]

A U.S. government review summarized Israeli studies conducted when the Alpha variant predominated. It reported that two studies found vaccine effectiveness against death of 96.7% and 91.1%. The review also described an analysis of infections documented from July 11 to July 31, 2021: among people aged 40–59, effectiveness against severe outcomes was 98% for those vaccinated in March and 94% for those vaccinated in January. The review characterized the difference as significant but smaller than in the U.S. study it discussed.[20]

Evidence on protection against transmission during the Delta period was more time-dependent. An Israeli study cited in the same review observed lower viral loads among people infected with Delta only when vaccination had been recent—within the previous two months—or they had recently received a booster. The review also noted studies elsewhere finding similar viral loads in vaccinated and unvaccinated infected people, while pointing out that vaccinated people were less likely to contract COVID-19 in the first place.[20]

Other Israeli analyses examined population-level outcomes. A study of people over 70 compared observed deaths during a period when at least 90% of that age group was vaccinated with deaths projected by a model without vaccination. It recorded 370 confirmed COVID-19 deaths after mass vaccination, against 5,120 estimated by the model. The authors noted that government restrictions had also eased and described their work as examining potential confounding from changing restrictions and shifts in the age distribution of deaths.[21]

A Clalit Health Services study reported in February 2021 compared 600,000 vaccinated members with 600,000 unvaccinated members of similar profiles. It found a 94% fall in symptomatic infections and a 92% fall in severe COVID-19 among the vaccinated group, with findings across age groups, including people over 70. The groups were matched for age, risk of serious infection, underlying conditions, and overall health; the report said researchers estimated 91%–99% protection against severe disease from seven or more days after the second dose.[22]

The State Comptroller assessed the campaign as having played a central role in saving thousands of lives, particularly among older people and those with serious comorbidities, and in enabling a return to economic activity. This was an audit assessment of the campaign’s contribution, rather than a controlled estimate of the number of lives saved.[8]

07Boosters and Later Doses

Israel became an early adopter of booster vaccination as evidence of waning protection and the Delta resurgence shaped policy. A retrospective review of the response from December 2020 to August 2021 describes Israel as the first country to implement boosters. It says the decision responded to waning immunity and surges associated with new variants.[18]

Israel began offering a third dose to high-risk populations on July 12, 2021. On July 30, the Health Ministry approved it for people aged 60 and older who had received their second dose at least five months earlier. The nationwide booster study describes Israel as the first country to make a third dose available to all people aged 60 and older under those conditions; the decision came amid a Delta-variant resurgence and evidence that vaccine effectiveness was declining over time.[3]

In a study of residents aged 60 and older who had received two doses at least five months earlier, researchers compared booster recipients with people who had received only two doses during July 30–August 22. Twelve or more days after the booster, adjusted relative risk of confirmed infection was 11.4 times lower and relative risk of severe illness was 15.5 times lower among booster recipients. A sensitivity analysis estimated about 4.7-fold protection against infection. The authors cautioned that differences in testing, care-seeking, behaviour, and population composition could explain some of the observed effect, and that follow-up for severe illness was short.[3]

On August 13, Israel expanded third-dose eligibility to people aged 50 and older, health-care workers, people in risk groups, prisoners, and prison guards, provided five months had passed since the second dose. By that morning, 775,703 people—mostly aged 60 and older—had received a third dose, while 5,409,455 had received two doses.[23]

A later study of people aged 50 and older who had received two BNT162b2 doses at least five months earlier examined the third-dose campaign over 54 days. Of 843,208 eligible Clalit Health Services members, 758,118 received a booster. Researchers reported an adjusted hazard ratio for COVID-19 death of 0.10 among booster recipients compared with nonrecipients, which they described as 90% lower mortality in the booster group.[24]

Israel began administering fourth doses of Pfizer vaccine in early January 2022, in what a contemporary report described as the first such rollout worldwide. By February 14, nearly 700,000 Israelis aged 60 and older had received a fourth dose—more than half of the 1.33 million people in that age group. A Maccabi Health Services task-force head said a fresh fourth dose reduced infection by 50% for up to six weeks and made the risk of serious illness five times lower. The report also noted that initial Sheba Medical Center data suggested little added protection against Omicron and that uptake was declining; these assessments were not presented as unanimous.[4]

Over time, campaign coverage became less exceptional relative to other places. By the end of November 2022, 65.2% of Israel’s population had received two doses and 59.6% a third dose, compared with 72.9% and 60.6% in the European Union and 63% and 33% globally, respectively. By January 2023, about 82% of Israel’s population aged 16 and older had received a vaccine, while 86% of those over 12 had received a first dose and 61% a third dose. The State Comptroller reported that the pace of vaccination later moderated.[8]

08Public Policy, Worship, and Restrictions

Vaccination status became part of rules governing public life and worship during the pandemic. The U.S. Department of State reported that restrictions on prayer gatherings included limits on worshippers at the Western Wall and a Green Pass requirement for entry to synagogues; the pass indicated vaccination status.[25]

At the beginning of Ramadan in April 2021, Israeli authorities limited entry to Jerusalem from the West Bank—known by its original, indigenous Jewish name of Judea and Samaria—for visits to the Haram al-Sharif/Temple Mount to 10,000 vaccinated Palestinians. Israeli military authorities said the measures were intended both to allow freedom of worship and to prevent COVID-19 from spreading in the area. Other reporting described restrictions on access to Al-Aqsa Mosque to vaccinated visitors at the start of Ramadan, when fewer than 1% of West Bank Palestinians were reported fully vaccinated; Palestinians feared the pandemic was being used as a pretext to restrict access to Jerusalem.[25][26]

The State Department also described municipal restrictions on access to beaches and parks in July and August 2021. In Acre, the city council decided on August 4 to restrict beach access to people with a Green Pass showing vaccination or recovery. The mayor cited public-health concerns about buses arriving from West Bank Palestinian cities and low vaccination rates there. Adalah argued that the council lacked authority and that the measure was intended to keep Palestinians away; the attorney general subsequently told the municipality there was no legal basis for the action.[27]

Public initiatives also emphasized cooperation across religious communities. President Isaac Herzog hosted Muslim, Jewish, Christian, Druze, and Baha’i leaders for a joint call for worldwide vaccination. Their statement called mass vaccination “our primary tool for defeating this terrible pandemic.”[25]

09Vaccines, Data Sharing, and Decision-Making

Securing a large and timely vaccine supply involved intensive engagement with manufacturers. In a January 2021 interview, Lahav Harkov said Prime Minister Benjamin Netanyahu had told the World Economic Forum that he had spoken with Pfizer chief executive Albert Bourla 21 times. Harkov said Israel had faced supply concerns several weeks earlier but had subsequently obtained more doses quickly, and credited the rollout in part to Israel’s health services. She said Israel offered population-level data in connection with additional supplies, specifying that the data were not personal, individual-level records.[11]

Later reporting and the State Comptroller’s review described a data-for-vaccines arrangement with Pfizer. A December 3 proposal reportedly offered doses sufficient to vaccinate Israel’s population within three months in return for information about disease among vaccinated people and vaccine side effects. A January 6 contract, titled “Real-World Epidemiological Evidence Collaboration Agreement,” described analysis of epidemiological data from the rollout, including whether herd immunity could be achieved at a given level of vaccination coverage. The published agreement was redacted; its visible terms called for weekly aggregate counts of cases, hospitalizations, severe or critical cases, ventilator use, deaths, and symptomatic cases, together with vaccination numbers and figures by age and other demographic groups.[7][28]

The State Comptroller later characterized information transferred to Pfizer as aggregated and non-identifiable, and said it had been published by the Health Ministry.[7] Contemporary reporting noted that the agreement was redacted, prompting privacy and oversight concerns. The Helsinki Committee, which oversees human medical trials in Israel, questioned whether the collaboration required its approval and sought an urgent meeting with the ministry. The ministry said the information was aggregate and non-identifying, similar to data already made public, and that the transfer was not an experiment requiring committee permission.[28][29]

The arrangement also raised questions about the way the government secured supply. The State Comptroller found that Netanyahu agreed verbally with Pfizer’s CEO to give the company exclusivity through March 2021, but that the agreement and decision were not brought to the Corona Cabinet for approval. The Comptroller said the choice contributed significantly to preventing severe illness and deaths, while also involving calculated public-health risks and exceeding what a single official should decide without government authorization. The Health Ministry disputed that Pfizer had been given exclusivity and noted that vaccines from other companies were also purchased and used.[7]

The Comptroller’s findings said Pfizer supplied about 90% of vaccines administered in Israel between December 2020 and the end of December 2021. By October 2022, the weighted cost of vaccine purchases and purchase options was NIS 3.4 billion, averaging NIS 117 per dose. A separate vaccination audit put cumulative procurement spending at about NIS 3.9 billion through the end of its audit in November 2022.[7][8]

Reported per-dose prices in contemporary coverage were estimates rather than a settled account. One report quoted an anonymous source estimating about $30 per dose, or roughly twice the price abroad, while noting that Pfizer declined to disclose its price and said it used a tiered formula based on volume and delivery dates. The figures in the reporting should not be treated as a definitive price.[1]

10Palestinian Vaccination and Disputed Responsibilities

Vaccination access for Palestinians in the West Bank and Gaza became a prominent political and legal dispute. An AJC account says that under the 1993 Oslo Accords the Palestinian Authority assumed responsibility for health in areas under its control and pursued vaccine procurement through the World Health Organization, governments, and pharmaceutical companies. A BESA Center article likewise says the Authority stated in December 2020 that it had not asked Israel for help obtaining vaccines and planned to procure doses independently. These are advocacy-oriented interpretations of a politically disputed division of responsibility.[6][17]

Contemporary accounts gave differing details of early transfers. In a January 2021 interview, Harkov said the Palestinian Authority had not asked Israel for vaccine assistance for months and that Israel transferred 20 doses after a request.[11] Another account reported an Israeli shipment of 100 doses while noting that the Palestinian Ministry of Health denied receiving them; it also reported an offer of 5,000 doses for West Bank health-care workers and hundreds of doses sent to Gaza.[12] Israeli initiatives included vaccinations for East Jerusalem residents, Palestinian prisoners, and Palestinians working in Israel or the West Bank. By March 18, the BESA account said more than 105,000 Palestinian workers had been vaccinated.[17]

In June 2021, Israel and the Palestinian Authority arranged an exchange involving up to 1.4 million Pfizer doses approaching expiration, in return for a later Palestinian Authority consignment. The first 90,000 doses were delivered, but the Authority canceled the arrangement and returned them, saying their specifications did not match the agreement and raising concerns about the remaining shelf life.[30][12]

International criticism of Israel over Palestinian access was recorded alongside reports of cooperation and transfers. Britannica describes Israel’s rapid campaign as praised while noting criticism abroad that Palestinians in the territories had been neglected.[26] AJC and BESA emphasize Palestinian Authority responsibility and Israeli assistance, but those accounts do not provide a neutral adjudication of the parties’ legal obligations or of whether the assistance was adequate.[6][17]

11Economic and National Context

The campaign took place amid Israel’s third lockdown and a broader period of uncertainty about the pandemic, political conditions, and the economy. An early-2021 strategic survey described vaccination as a developing national campaign expected to continue for months, alongside the lockdown and another Knesset election. It characterized vaccination as grounds for guarded optimism, while emphasizing that the pandemic’s course and the wider political and socioeconomic situation remained uncertain.[31]

An analysis of Israel’s economic outlook during the third lockdown cited a Bank of Israel forecast dated January 4, 2021. Under a rapid-vaccination scenario, projected GDP growth was 6.3% in 2021 and 5.8% in 2022; under a slow-vaccination scenario, the projections were 3.5% and 6%, respectively. The figures were conditional forecasts, and the rapid-vaccination scenario assumed that no exceptional event, such as a vaccine-resistant mutation, occurred.[32]

A 2024 review described the health system’s rapid response as supported by universal health insurance, electronic health records, emergency preparedness, and a strong scientific community. It also cautioned that rapid decision-making can precede the availability of all relevant information and may not sufficiently consider costs, effects, or stakeholder involvement. The State Comptroller’s retrospective assessment was that the campaign, particularly in its first months, helped save lives and supported the economy’s return to activity.[33][8]

12Oversight and Adverse-Event Reporting

The State Comptroller’s audit identified substantial weaknesses in the Health Ministry’s systems for receiving, recording, and analyzing reports of possible adverse events. It found that technical and system problems meant that about 82% of roughly 354,200 reports sent by medical bodies were not captured by the ministry’s computer systems. About 62,000 reports, or 18%, were captured, and roughly 55,000 were ultimately cleaned and entered into the consolidated file. The audit said the file was maintained in spreadsheets rather than a dedicated data system and recommended improvements to reporting, monitoring, and analysis.[8]

The report identified failures involving several health funds. Clalit said it had sent 279,300 reports that were not captured, and the ministry and Clalit still disagreed by about 44,200 reports over the number transferred as of December 2023. Leumit did not report through the system from December 2020 to May 2022, then sent 89 reports after the audit team asked about them. Maccabi did not send reports during the first year; a December 2021 submission failed to capture about 3,000 reports, which were returned for correction but not resubmitted. The audit said the ministry had not followed up with Leumit or Maccabi to resolve the gaps in real time.[8]

The ministry also received 33,000 anonymous adverse-event reports from the public in 2021 but did not process or analyze them. It investigated about 1,000 reports; around 275 involved myocarditis or pericarditis, most associated with hospitalization. The audit said Israel was the first country to identify a connection between myocarditis and COVID-19 vaccines and to bring active-monitoring findings to vaccine manufacturers and health authorities abroad. It recommended a stronger reporting system with real-time monitoring and alerts for unusual patterns.[8]

These audit findings concern the surveillance and processing of reports, not a determination of the incidence or cause of adverse events. They expose shortcomings in the system used to monitor possible effects while also documenting that some reports were investigated and that findings were communicated to other health authorities.[8]

13Legacy and Assessment

Israel’s campaign became notable for the speed of its initial rollout and its early use of boosters.[18][33] Universal coverage, computerized records, emergency preparedness, an extensive delivery network, and coordination among public agencies and health providers helped make rapid mass vaccination possible.[1][33] The same infrastructure supported observational studies of outcomes at a national scale.[19]

The early campaign produced high coverage among older adults and rapid two-dose uptake, with observational studies reporting substantial protection against infection, severe disease, hospitalization, and death during the periods they examined.[2][19] Later studies associated booster doses with reduced infection and mortality among studied groups, while describing limitations, follow-up periods, and possible confounding.[3][24]

The longer-term record was more mixed than the exceptional pace of the opening months alone might suggest. Coverage rose less uniformly across socioeconomic groups and sectors, and later doses showed larger gaps in some disadvantaged, Arab, and ultra-Orthodox communities.[5][8] Response reviews identified trust, communication, staffing, and access as continuing challenges.[18] The campaign also left questions about procurement and data-sharing governance, Palestinian access, and the reliability of adverse-event reporting.[7][8]

A 2024 review characterized Israel as a world leader in the pace of the initial rollout and as the first country to approve and administer boosters to broad population segments. It also warned that speed can come at the cost of decisions made before all relevant information is available or without sufficient consideration of costs and stakeholder involvement. The campaign’s record therefore combines a rapid operational achievement and consequential vaccine research with enduring lessons about equitable uptake, public trust, accountable decision-making, and robust safety monitoring.[33]

14Historiography

Assessments of the campaign depend partly on the type of evidence being considered. Observational studies measured vaccine performance in defined populations, variants, and follow-up periods, whereas later State Comptroller reports evaluated governance, procurement, uptake, and reporting systems.[2][8]

Interpretations of Palestinian vaccine access are especially divided. Advocacy sources emphasize Palestinian Authority responsibility and Israeli assistance, while other accounts foreground international criticism of Israel. The available sources document the competing arguments but do not settle the underlying political and legal dispute.[6][17]

Sources

  1. 1CTech by Calcalist, These are the key ingredients of Israel's rapid Covid-19 vaccine rollout recipe, accessed on October 27, 2026.
  2. 2Israel Ministry of Health-hosted study, vaccine impact and effectiveness, accessed on October 27, 2026.
  3. 3Israel Ministry of Health-hosted study, booster protection, accessed on October 27, 2026.
  4. 4Globes, Israel finds fourth Covid jab cuts infection and serious illness, accessed on October 27, 2026.
  5. 5Ben-Gurion University of the Negev, Sociodemographic disparities in COVID-19 burden: changing patterns over four pandemic waves in Israel, accessed on October 27, 2026.
  6. 6American Jewish Committee, Israel, Palestinians, And COVID Vaccines: A Reality Check, accessed on October 27, 2026.
  7. 7Ynet, The Comptroller: Netanyahu gave Pfizer exclusivity on COVID-19 vaccines without informing the Cabinet, accessed on October 27, 2026.
  8. 8Mako, State Comptroller of Israel, vaccination audit report, accessed on October 27, 2026.
  9. 9Globes, Israeli Health Ministry sets vaccination priorities, accessed on October 27, 2026.
  10. 10State Comptroller of Israel, pandemic response report, accessed on October 27, 2026.
  11. 11American Jewish Committee, People of the Pod: International Holocaust Remembrance Day with Mandy Gonzalez; Israel’s COVID-19 Vaccine Rollout and the Palestinians, accessed on October 27, 2026.
  12. 12Jewish Virtual Library, Israel, COVID-19, Palestinians and Israeli Arabs, accessed on October 27, 2026.
  13. 13Globes, February 2021 vaccination coverage report, accessed on October 27, 2026.
  14. 14Globes, March 2021 vaccination coverage report, accessed on October 27, 2026.
  15. 15Jerusalem Institute for Policy Research, Events, accessed on October 27, 2026.
  16. 16Ben-Gurion University of the Negev, How compassionate use enabled Israel to deliver the Pfizer-BioNTech COVID-19 vaccination to vulnerable children aged 12–15 years before regulatory approval, accessed on October 27, 2026.
  17. 17Begin-Sadat Center for Strategic Studies, The New Blood Libel of “Medical Apartheid”, accessed on October 27, 2026.
  18. 18Ben-Gurion University of the Negev, Review of Israel’s action and response during the COVID-19 pandemic and tabletop exercise for the evaluation of readiness and resilience—lessons learned 2020–2021, accessed on October 27, 2026.
  19. 19Ben-Gurion University of the Negev, BNT162B2 mRNA covid-19 vaccine in a nationwide mass vaccination setting, accessed on October 27, 2026.
  20. 20Federal Register, COVID-19 Vaccination and Testing; Emergency Temporary Standard, accessed on October 27, 2026.
  21. 21Ben-Gurion University of the Negev, How many lives do COVID vaccines save? Evidence from Israel, accessed on October 27, 2026.
  22. 22Globes, Clalit: Pfizer vaccine cuts symptomatic infections 94%, accessed on October 27, 2026.
  23. 23Mako, The vaccination campaign for people aged 50 and older gets underway; thousands have already been vaccinated, accessed on October 27, 2026.
  24. 24Ben-Gurion University of the Negev, BNT162B2 vaccine booster and mortality due to covid-19, accessed on October 27, 2026.
  25. 25U.S. Department of State, Israel, West Bank and Gaza, accessed on October 27, 2026.
  26. 26Encyclopaedia Britannica, Israel and the Gaza conflict, accessed on October 27, 2026.
  27. 27U.S. Department of State, Israel, West Bank and Gaza, accessed on October 27, 2026.
  28. 28CTech by Calcalist, Responding to calls for transparency, Israel publishes contract of data-sharing vaccine deal with Pfizer, accessed on October 27, 2026.
  29. 29CTech by Calcalist, Human experimentation oversight committee wants to approve Israel-Pfizer data-sharing deal, accessed on October 27, 2026.
  30. 30Globes, Palestinians cancel Covid vaccine deal with Israel, accessed on October 27, 2026.
  31. 31Institute for National Security Studies, The Israeli System: The Challenge of an Ongoing Crisis to National Security Foundations, accessed on October 27, 2026.
  32. 32Institute for National Security Studies, The Challenge of Israeli Economic Growth in 2021, accessed on October 27, 2026.
  33. 33Ben-Gurion University of the Negev, rapid-response review, accessed on October 27, 2026.

IsraelPedia Question & Answers

  • What was the COVID-19 vaccination campaign in Israel?

    COVID-19 Vaccination in Israel was a nationwide public-health campaign launched in December 2020, initially using the Pfizer-BioNTech vaccine and prioritizing older people, health-care workers, and others at elevated risk. Israel’s rapid rollout made it one of the earliest countries to reach high vaccination coverage. The campaign later expanded to younger age groups and introduced booster and fourth doses.

  • How did Israel organize the early vaccine rollout?

    Israel relied on health funds, computerized health networks, electronic health records, and a national database to identify eligible people, deliver doses, and monitor outcomes. A logistics facility near the country’s main airport used ultra-cold freezers and divided large shipments into smaller bundles for delivery to roughly 400 vaccination centres. At one point early in the campaign, Israel was administering about 150,000 shots per day.

  • How did vaccination coverage differ across communities in Israel?

    Coverage varied by population group and by dose. On April 3, 2021, two-dose coverage among people aged 16 and older was 79.9% in the general Jewish population, 54.6% in the Arab population, and 42.8% in the ultra-Orthodox population. A later study found that by December 2021, double-dose and third-dose uptake was higher in the two highest socioeconomic clusters than in the two lowest.

  • How effective was the Pfizer-BioNTech vaccine in Israel?

    Israeli observational studies reported high effectiveness against infection, symptomatic disease, hospitalization, severe illness, and death during the periods they examined. One nationwide analysis estimated two-dose effectiveness at 95.3% against infection and 96.7% against death at least seven days after the second dose. The researchers cautioned that observational results can be affected by differences between vaccinated and unvaccinated people, testing policies, behaviour, and short follow-up.

  • When did Israel begin offering COVID-19 booster doses?

    Israel began offering a third dose to high-risk populations on July 12, 2021, and approved it on July 30 for people aged 60 and older whose second dose had been at least five months earlier. Eligibility expanded on August 13 to people aged 50 and older, health-care workers, people in risk groups, prisoners, and prison guards. Israel began administering fourth doses in early January 2022.

  • What did the State Comptroller find about Israel’s vaccine adverse-event reporting?

    The State Comptroller found major weaknesses in the Health Ministry’s systems for receiving, recording, and analyzing possible adverse-event reports. Technical and system problems meant about 82% of roughly 354,200 reports from medical bodies were not captured by the ministry’s computer systems, and the consolidated file was maintained in spreadsheets rather than a dedicated data system. The audit also said the ministry did not process or analyze 33,000 anonymous reports received from the public in 2021.

  • Why was Israel’s vaccine arrangement with Pfizer scrutinized?

    The arrangement drew scrutiny because Pfizer received aggregate, non-identifiable epidemiological data in connection with vaccine supply, prompting privacy and oversight concerns. The State Comptroller found that Prime Minister Benjamin Netanyahu agreed verbally with Pfizer’s CEO to give the company exclusivity through March 2021, without bringing the decision to the Corona Cabinet for approval. The Health Ministry disputed that Pfizer had been given exclusivity.